Scribe, Jen­nifer Doud­na's newest start­up, nabs a mega-round and a vo­cal in­vestor

5 years ago
Financing

A pair of Lyell founders look to shift the cell ther­a­py par­a­digm — and they've got $30M to get their plan off the ...

5 years ago
Financing
Cell/Gene Tx

Bet­ting ear­ly on an AI niche, RA Cap­i­tal seeds a young founder's quest to un­lock 'Holy Grail' tar­gets

5 years ago
Financing
Startups

Biotech pi­o­neer and start­up in­vestor John Mar­tin, who built Gilead in­to a pow­er­house play­er, has died

5 years ago
People

Covid-19 roundup: As­traZeneca vac­cine halt­ed in Ger­many for be­low-60 pop­u­la­tion; Pfiz­er says Covid-19 vac­cine has ...

5 years ago
Coronavirus

Piv­ot­ing to­ward neu­ro­mus­cu­lar dis­eases and Duchenne, En­tra­da locks down $116M crossover round

5 years ago
Financing

Neil Ku­mar’s Bridge­Bio team locks in a $2.4B part­ner­ship as their next drug gets a snap re­view at the FDA

5 years ago
Deals

How Biden’s in­fra­struc­ture plan will go af­ter bio­phar­ma com­pa­nies be­yond drug pric­ing

5 years ago
Pharma

Af­ter leav­ing Mer­ck­'s C-suite, Mike Nal­ly turns up at the helm of a Flag­ship ma­chine learn­ing com­pa­ny

5 years ago
People

Look­ing to crack down on big bio­phar­ma M&A deals, FTC sues to block Il­lu­mi­na's $8B Grail ac­qui­si­tion

5 years ago
Deals
FDA+

Am­gen takes a swing at re­gen­er­a­tive im­munol­o­gy with $721M ac­qui­si­tion of Rodeo Ther­a­peu­tics

5 years ago
Deals

Re­call re­port: Zy­dus re­calls her­pes drug af­ter crys­tal­liza­tion com­plaints; Alem­bic pulls low blood pres­sure drug for ...

5 years ago
Manufacturing

In­tel­lia an­nounced a new tool for gene edit­ing. Aca­d­e­mics said they rewrote his­to­ry

5 years ago
Discovery

House Dems seek to over­turn Trump-era rule that could gut FDA’s reg­u­la­tions

5 years ago
Pharma
FDA+

Mer­ck lines up a buy­out deal for soon-to-be wom­en's health spin­out

5 years ago
Deals

Armed with Pfiz­er's ADC plat­form, Pyx­is scores $152M round to shoot for the clin­ic while tak­ing its time on I/O ...

5 years ago
Financing

For­ma sees da­ta 'sup­port­ing' sick­le cell ther­a­py dos­ing lev­els; Lian­Bio teams with Tar­sus for eye ir­ri­ta­tion in Chi­na

5 years ago
News Briefing

HHS reg­u­la­to­ry agen­da for 2021 is light on new pro­posed and fi­nal FDA rules

5 years ago
Pharma
FDA+

Af­ter dis­miss­ing CFO over 'i­nap­pro­pri­ate mes­sages,' Eli Lil­ly faces new ac­cu­sa­tions of sex­u­al dis­crim­i­na­tion and ...

5 years ago
Pharma

The IBD mar­ket is set to soar to $32B. Ab­b­Vie could be the big win­ner, but there's meat left on the bone — top ...

5 years ago
Pharma

No­var­tis dives even deep­er in­to ra­di­oli­gands, notch­ing li­cens­ing deal with iTher­a­nos­tics for mul­ti­ple com­pounds

5 years ago
Deals

BioN­Tech makes a splash with $10B+ pro­jec­tion for 2021 Covid-19 vac­cine sales

5 years ago
Coronavirus

Go­ing head-to-head with Mer­ck on I/O, Genen­tech vets raise fresh round and en­ter clin­ic

5 years ago
Financing

Af­ter pi­lot project, Take­da inks $500M pact to tap in­to a Ke­van Shokat pro­tégé's co­va­lent small mol­e­cule fish­ing ...

5 years ago
Deals
First page Previous page 714715716717718719720 Next page Last page
A service from the Financial Times